Improved Diagnosis for Mendelian Genetic Disorders
First the ''good news'': the contribution of modern genetics and genomics to the diagnosis of Mendelian genetic disorders has been nothing short of spectacular. The number of human single-gene disorders with a known molecular genetic cause has risen from less than 5 in 1982, to approximately 150 in 1990, and to nearly 3,000 in 2011 (http://omim.org). Precise DNA diagnosis in approved clinical testing laboratories is available for many of these disorders, and testing on a research basis can be obtained for a significant subset of the remaining diseases. Although ambiguity still remains for some sequence findings (e.g., ''variants of unknown significance''), definitive diagnosis can often be established by DNA testing, and once a familial mutation is known, testing of nearly perfect sensitivity and specificity is then available for other at-risk family members, including prenatal and preimplantation diagnoses. These advances have led to the near elimination of select autosomal-recessive diseases in specific populations, such as b-thalassemia in parts of the Mediterranean and TaySachs disease among Ashkenazi Jews (Zlotogora, 2009) . Though the full power of genetic diagnosis has not yet been fully realized, major progress is clear, and the impact of DNA testing on single-gene disorders, particularly with the advent of next-generation sequencing, is likely to expand dramatically over the next decade.
Treatment for Mendelian Genetic Disorders
Now for the ''bad news'': in contrast to the remarkable impact on diagnosis, the contribution of modern genetics and genomics to the treatment of most Mendelian genetic disorders has been, with a few notable exceptions, a disappointing failure. Among the 3,000 single-gene disorders for which the responsible gene has been identified, only a handful (<1%) have been translated directly into new therapies. Most of this success has been restricted to diseases due to enzyme deficiencies, such as hemophilia and the lysozomal storage diseases. However, for most genetic diseases, little has changed in treatment since the discovery of the responsible gene. Where modest improvement in therapy has been seen, this has generally been empiric and not the direct result of knowing the underlying genetic defect. Examples include muscular dystrophy, whose gene was identified in 1986, cystic fibrosis (1989), and Huntington disease (1993) . Sickle cell anemia provides a particularly humbling example for the biomedical research community. Its molecular basis has been understood at the 5.5 Å level since 1960 (Perutz et al., 1960) . However, current therapy is still largely empiric and not derived from a sophisticated understanding of hemoglobin structure and sickle cell anemia molecular pathogenesis.
Chronic myelogenous leukemia (CML) offers a striking exception for which understanding genetic pathogenesis has indeed had a striking impact on treatment. Imatinib (Gleevec), a targeted therapeutic against the unique fusion gene product (BCR/ABL) found in all CML patients, has profoundly altered the prognosis for patients with this disease. Despite the initial enthusiasm that designer drugs of this type would soon become a routine follow-on to the discovery of any pathogenic gene, few such therapies with an impact of this magnitude have yet emerged. It has become increasingly clear that the path for translation of basic genetic findings into new therapeutics is not an easy one.
Although 3,000 Mendelian diseases can now be diagnosed by DNA testing, is this always of direct clinical value to the patient? Medical test ordering by physicians often follows a logic similar to Mallory's decision to climb Mount Everest, simply ''because it's there.'' This approach has made unrestrained diagnostic testing a key contributor to runaway health care costs. A transition toward evidence-based medicine will increasingly demand that diagnostic tests, including DNA testing, be restricted to those settings wherein a significant impact on treatment and medical management is anticipated. It is here that our disappointing success rate in translating genetic discovery into improved medical treatment dampens the significance of our triumph in the diagnostic arena. Unfortunately, a significant fraction of DNA diagnostic tests currently performed does not meet this standard of evidence-based medical justification.
For example, one of the most commonly performed genetic diagnostic tests in the US today is for factor V Leiden, a common human polymorphism that predisposes to venous thrombosis. However, the results of this test are of limited or no value in guiding current medical therapy (Middeldorp, 2011) .
Though modern genetics and genomics have had a transforming impact on our understanding of Mendelian human genetic disorders, direct translation to improved treatment remains elusive for most patients. This relative failure to date should not be a cause for resignation or despair, but rather a call to redouble our efforts. The path from basic discovery to effective therapy is usually a long and arduous one, and generally unpredictable. Recent history simply demonstrates that identifying something as broken is much easier than fixing it.
Complex Genetic Disorders
Single-gene disorders are estimated to account for approximately 9% of childhood mortality and probably less than 2% of overall hospital admissions in the US (Korf et al., 2007) . The vast majority of health care costs are devoted to the treatment of common complex disorders such as coronary artery disease, stroke, diabetes, hypertension, and cancer, which all appear to have large, heritable components. The ''common disease/ common variant'' hypothesis has been tested by genome-wide association studies (GWAS) for over 220 diseases or traits (Hindorff et al., 2011) . Over 1,300 highly significant genetic risk loci have been identified, though nearly all with very modest effect (allelic odds ratios generally < 1.5) and in aggregate accounting for only a small fraction of the overall genetic risk (Manolio et al., 2009) .
Is information from GWAS clinically useful in guiding medical management or choice of therapy? At present, the clear consensus among clinical genetic experts is a resounding ''no.'' One prime example is type 2 diabetes, where extensive single-nucleotide polymorphism (SNP) testing adds little to the much greater predictive value of family history and body mass index (Lyssenko et al., 2008) . The lack of demonstrated diagnostic or therapeutic utility has not dissuaded the enthusiastic direct-to-consumer (DTC) marketing of whole-genome SNP analysis for self-diagnosis of risk for a broad array of diseases and common human traits. Though the technical validity of SNP calling seems high, risk prediction from similar data varies dramatically between different DTC companies, often in opposite directions (Ng et al., 2009 ). The potential negative impact of DTC genetic testing on medical practice and health care cost containment has led to calls for increased regulation and oversight.
Despite limited direct clinical payoff to date, GWAS have nonetheless provided important advances in our understanding of several complex genetic diseases. Examples include entirely unanticipated insight into the role of complement factor genes in the pathogenesis of age-related macular degeneration (de Jong, 2006) and the discovery of the BCL11A gene as a critical regulator of fetal hemoglobin levels and the long-sought-after basis for the fetal to adult globin switch (Sankaran et al., 2009 ). In addition, the observation that common SNPs in aggregate generally account for <10%-20% of overall genetic risk for most complex diseases has sparked new efforts to identify the genetic basis for the remaining ''missing'' heritability (Manolio et al., 2009) .
Pharmacogenomics
There has been considerable enthusiasm that the identification of common human genetic variants would accurately predict drug response and toxicity, allowing precise tailoring of individualized or ''personalized'' treatments for patients based on their specific disease and genetic makeup. Nonetheless, progress in this area remains limited and has not yet proven as straightforward as initially thought. Although there are several clear-cut associations of specific genetic variants with drug toxicity, genetic screening prior to treatment has not yet become a standard part of medical care. As in disease diagnostics, pharmacogenomic testing has often been greeted with naive enthusiasm and advocated well in advance of solid evidence for clinical utility. A case in point is CYP2/C9 and VKORC1 genotyping to predict response to warfarin, a widely used oral anticoagulant for which precise dosing is critical (too low a dose leads to inadequate efficacy as an anticoagulant and too high a dose to excessive bleeding). Common variants in these two genes account for 30% of the variability in the individual response to warfarin, leading the U.S. Food and Drug Administration to modify warfarin labeling to suggest CYP2/C9 and VKORC1 genotyping. However, this testing has not yet been demonstrated to be of practical clinical value in decreasing bleeding complications or increasing anticoagulant efficacy and is rarely used in clinical practice (Rosove and Grody, 2009 ).
Where Do We Go from Here? The impact of next-generation sequencing on human genetics, both diagnostically and therapeutically, is likely to be transformational. With decreased cost and improved quality over the next 5-10 years, whole-genome sequencing may replace conventional newborn screening in much of the developed world. Initially, only those genes for which immediate diagnosis in a newborn is of clear value for directing medical management are likely to be evaluated, including the 20-30 genes comprising current newborn screening panels, with the rest of the sequence archived for later use. The list of such actionable Mendelian genetic disorders will undoubtedly expand with time. The availability of full genome sequences for large fractions of the patient population, together with implementation of a uniform electronic medical record, should enable an entirely new scale of genetic epidemiologic health outcomes research. Along with these advances, issues of informed consent and genetic privacy, as well as ethical considerations related to prenatal and preimplantation intervention, will pose increasingly complex challenges.
The anticipated flood of sequencing data, along with the development of new computational and conceptual tools to analyze it, are likely to yield profound new insights into the pathogenesis of human disease, the diagnosis of complex genetic disorders, and the accurate prediction of drug efficacy and toxicity, leading to improved treatment selection. The near future promises to be a very exciting time for biomedical research, perhaps finally providing the tools required to realize the promise of translating basic scientific discovery into improved outcomes for patients.
